Introduction {#section5-1753466620939507}
============

Dyspnea and exercise intolerance are among the most debilitating symptomatic manifestations of chronic obstructive pulmonary disease (COPD).^[@bibr1-1753466620939507]^ Besides its effects on exercise tolerance, persistent dyspnea independently predicts poor clinical outcomes including exacerbations, hospitalizations and even mortality.^[@bibr2-1753466620939507]^ Together, dyspnea and exercise intolerance lead to a vicious circle that promotes the adoption of a sedentary lifestyle, another important predictor of mortality in COPD.^[@bibr3-1753466620939507],[@bibr4-1753466620939507]^

Alleviating dyspnea and improving exercise tolerance are important therapeutic goals when caring for patients with COPD.^[@bibr5-1753466620939507]^ Several clinical trials have confirmed the ability of long-acting bronchodilators to enhance exercise tolerance and to reduce the perception of dyspnea in patients with moderate to severe COPD.^[@bibr6-1753466620939507][@bibr7-1753466620939507][@bibr8-1753466620939507][@bibr9-1753466620939507][@bibr10-1753466620939507]--[@bibr11-1753466620939507]^ Central to these benefits is the efficacy of long-acting bronchodilators to improve expiratory flows and to reduce operating lung volumes during exercise, which translates to less perceived dyspnea.^[@bibr6-1753466620939507][@bibr7-1753466620939507][@bibr8-1753466620939507][@bibr9-1753466620939507][@bibr10-1753466620939507][@bibr11-1753466620939507][@bibr12-1753466620939507][@bibr13-1753466620939507]--[@bibr14-1753466620939507]^

In order to specifically assess the efficacy of COPD treatments to reduce exertional dyspnea, we developed the 3-minute constant speed shuttle test (3-min CSST).^[@bibr15-1753466620939507],[@bibr16-1753466620939507]^ The main feature of this test is that it allows measuring dyspnea scores at fixed time points, including at the end of the test, enabling pre- and post-intervention comparisons with concrete data. Another important characteristic of the 3-min CSST is that the walking speed is externally imposed, and is designed to produce a standardized exercise stimulus to induce dyspnea. This is not the case for the self-paced 6-min walking test which, by design, does not allow for pre- and post-intervention comparisons of dyspnea perception to be made at a standardized exercise stimulus.^[@bibr17-1753466620939507]^ Lastly, this test allows for dyspnea measurement during walking, which is the most prevalent and problematic activity of daily life for patients with COPD.^[@bibr18-1753466620939507]^ The feasibility and reproducibility of the 3-min CSST have been documented in our previous work.^[@bibr15-1753466620939507]^ We also demonstrated the sensitivity of this test to detect reduced dyspnea perception after bronchodilation with ipratropium bromide compared with placebo in patients with COPD.^[@bibr16-1753466620939507]^ More recently, this exercise methodology was employed to document the added benefit of dual bronchodilation with tiotropium/olodaterol fixed dose combination to reduce exertional dyspnea compared with tiotropium alone in patients with COPD.^[@bibr19-1753466620939507]^

Considering the well-documented bronchodilation efficacy of indacaterol/glycopyrronium fixed dosed combination^[@bibr20-1753466620939507]^ and its capacity to alleviate patient-reported dyspnea during activity of daily life compared with placebo and tiotropium,^[@bibr21-1753466620939507]^ we designed this randomized controlled, double-blind cross-over study to compare the effects of dual bronchodilation with indacaterol/glycopyrronium *versus* bronchodilator monotherapy with tiotropium on exertional dyspnea in patients with moderate to severe COPD during the 3-min CSST. The impact of these therapies on expiratory flows and lung volumes, health status, and dyspnea during activities of daily life was also compared. We hypothesized that indacaterol/glycopyrronium would be superior to tiotropium at improving exertional dyspnea during the 3-min CSST, lung function and quality of life in patients with COPD.

Methods {#section6-1753466620939507}
=======

Study design {#section7-1753466620939507}
------------

This was a randomized, cross-over and double-blind multicenter trial. The primary objective was to compare the effects of indacaterol 110 µg/glycopyrronium 50 µg *versus* tiotropium 18 µg on Borg dyspnea score at the end of the 3-min CSST after 3 weeks of treatment in patients with moderate to severe COPD. Secondary outcomes included the assessment of (a) Borg dyspnea score at the end of the 3-min CSST after the first dose of study medication; (b) spirometry and lung volumes at rest, after the first dose of study medication and after 3 weeks of treatment; and (c) health status using the COPD Assessment Test (CAT)^[@bibr22-1753466620939507]^ and patient-reported dyspnea during activity of daily life with the Mahler Transition Dyspnea Index (TDI).^[@bibr23-1753466620939507]^ Lastly, we documented the cardiopulmonary response during the 3-min CSST with both study medications. Our protocol was registered on [ClinicalTrials.gov](http://ClinicalTrials.gov) \[[ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT02567214\]. This investigator-initiated research was funded by Novartis AG, which also provided the medications and the placebo used for the study. The sponsor had the opportunity to read the manuscript with no obligation for the authors to incorporate the comments that were made.

Study participants {#section8-1753466620939507}
------------------

Participants were recruited from the pulmonary clinics of three university-affiliated hospitals in Canada (Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval in Quebec City, McGill University Health Center in Montreal and Kingston General Hospital, Queens University in Kingston). Participants were selected on the basis of (a) moderate to severe COPD with a post-bronchodilator forced expiratory volume in 1 s (FEV~1~) between 30% and 79% of the predicted value, an FEV~1~/forced vital capacity (FVC) ratio of \<70%, and evidence of hyperinflation at rest \[functional residual capacity (FRC) \>120% of predicted value\]; (b) aged over 50 years; (c) a cigarette-smoking history \>10 pack-years; and (d) a Borg dyspnea score of at least 4 points during the baseline 3-min CSST. The main exclusion criteria were a COPD exacerbation less than 2 months prior to the study, a current diagnosis of asthma, pulsed arterial O~2~ saturation (SpO~2~) \<85% at rest or during exercise, the presence of another pathology that could influence exercise tolerance and use of home oxygen. Participants experiencing a COPD exacerbation during the study were not allowed to continue. Each institutional research ethics board approved the study and all participants signed an informed consent form.

Visits and follow up {#section9-1753466620939507}
--------------------

The study required seven visits ([Figure 1](#fig1-1753466620939507){ref-type="fig"}): three during the run-in and familiarization phase (V1--V3) and two during each of the two treatment phases (V4--V7). At V1, the inclusion/exclusion criteria were reviewed and written informed consent obtained. Spirometry, lung volumes and diffusion capacity (D~L~CO) were then measured to confirm study eligibility. V2 included a spirometry, a maximal incremental shuttle walking test (ISWT) and completion of the CAT. Participants were then familiarized with the 3-min CSST by doing two practice tests. At V3, patients performed two or three 3-min CSST to determine the shuttle speed that would produce a Borg dyspnea score of at least 4 points (moderate) while being sustainable for the entire 3-min test duration. Participants then entered the first treatment phase, during which they received one of the two study treatments: indacaterol 110 μg/glycopyrronium 50 μg (Ultibro^®^) once daily (OD) administered in a fixed dose combination with the Breezhaler^®^ device (Novartis AG) + placebo OD administered with the Handihaler^®^ device (Boehringer Ingelheim) or placebo OD administered with the Breezhaler^®^ device + tiotropium 18 μg (Spiriva^®^) OD administered with the Handihaler^®^ device. The duration of each treatment phase was 3 weeks. There was a 2-week washout period between the two treatment phases. V4 and V6 were the baseline visits for each treatment phase (except for Borg dyspnea score during the 3-min CSST, which was determined at V3). Participants performed spirometry and lung volumes measurements before and 1 h 20 min after receiving the study medication. One 3-min CSST was then performed 2 h 25 min after dosing, at the shuttle speed that was determined during V3. The same procedures were repeated at the end of each study phase (V5 and V7). Total study duration was 11 weeks.

![Study design.\
CSST, constant speed shuttle test; ICF, informed consent form; ISWT, incremental shuttle walking test; PFT, pulmonary function tests.](10.1177_1753466620939507-fig1){#fig1-1753466620939507}

Randomization and study blinding {#section10-1753466620939507}
--------------------------------

At V4, treatment sequence was randomized in a 1:1 ratio and stratified by site using a centralized computerized system. A numbered envelope associated with a specific treatment order was then delivered to the study team at each site. Only the study pharmacist could associate the number on the envelope with the corresponding treatment sequence. Study blinding was only broken after completion of data analysis. Study medications were pre-packaged; placebo and active treatments had the same external appearance.

Allowed medication during the study {#section11-1753466620939507}
-----------------------------------

After confirming study eligibility and throughout the 3-week run-in period, participants received open-label ipratropium (Atrovent^®^ MDI 20 μg/puff, four puffs QID, Boehringer Ingelheim). This medication was stopped 12 h before V3. Ipratropium was also allowed during the washout periods and was stopped 12 h before V4 and V6. As-needed salbutamol (Ventolin^®^ MDI 100 μg/puff, two puffs every 3--4 h PRN, GlaxoSmithKline) was allowed throughout the study, except that it had to be stopped 6 h prior to V3, V4, V5, V6 and V7. Long-acting bronchodilators were prohibited after V1 and throughout the study. Inhaled corticosteroids were continued at the same dosage as before the study. Phosphodiesterase-4 inhibitors and leukotriene antagonists were also permitted.

Measurements {#section12-1753466620939507}
------------

### Pulmonary function testing {#section13-1753466620939507}

Spirometry, lung volumes and D~L~CO were measured according to standard operating procedures. Measured values were expressed as percentages of their normal predicted values.^[@bibr24-1753466620939507]^

### ISWT {#section14-1753466620939507}

The ISWT was performed to characterize the exercise capacity of the study participants and to exclude those with an exercise-induced desaturation (SpO~2~ \<85%). As originally described by Singh *et al*.^[@bibr25-1753466620939507]^ the ISWT was performed in a hospital corridor on a flat 10-m course. The course was identified by two cones, each positioned 0.5 m from either end to allow participants to turn around the cone without the need for abrupt changes in direction. Participants walked at a predetermined pace as dictated by an audio signal. Walking speed was initially set at 0.50 m/s and then increased by 0.17 m/s every minute until the participants reached symptom limitation. No encouragement was given to patients throughout the test to avoid influencing exercise performance.^[@bibr26-1753466620939507]^

### Dyspnea questionnaires and CAT {#section15-1753466620939507}

The baseline dyspnea index was administered at baseline (V4 and V6), while the TDI and CAT were administered at the end of each treatment phase (V5 and V7), prior to dosing.

### 3-min CSST {#section16-1753466620939507}

Participants were instructed to walk in a corridor at a constant and externally imposed speed for 3 minutes and were asked to rate their dyspnea and leg fatigue with Borg's modified 0--10 scale^[@bibr27-1753466620939507]^ at prespecified moments during the test and at the end. Participants were directed to follow the audio signal for the entire 3 min of the test or until they became symptom limited. They were instructed to walk between two cones set up in the hospital corridor, positioned as for the ISWT, pacing their speed in a way not to wait at the cones for the next audio signal. At V3, and following a published algorithm for shuttle speed selection,^[@bibr19-1753466620939507]^ patients were asked to perform at least two tests at two different speeds in order to determine, among the five different walking speeds (2.5, 3.25, 4, 5, and 6 km/h), the highest shuttle speed that could be sustained for the entire 3 min and that would produce a Borg dyspnea score of at least 4 points at end-exercise. In doing so, our objective was to induce a sufficiently high level of dyspnea to be amenable to therapy. If patients were not able to carry through the 3 min at 2.5 km/h or could not reach a Borg dyspnea score of at least 4 points at the quickest speed, they were excluded.

### Cardiac and ventilatory measures {#section17-1753466620939507}

During each exercise test, minute ventilation (VE), breathing frequency (B~f~) and tidal volume (VT) were measured breath-by-breath using a portable cardiopulmonary exercise testing system (Jaeger^®^ Oxycon Mobile), calibrated according to the standard operating procedures. These values were obtained by averaging the last 15 s of each minute.

### Safety monitoring {#section18-1753466620939507}

Participants were screened at each visit for any adverse event and were invited to contact the team if any symptom or medical event appeared during the study, namely a COPD exacerbation, a hospitalization, intolerance to treatment and/or any other significant event. All adverse events were reviewed to assess whether the study drugs or the testing could be the cause of these events. Vital signs and 12-lead electrocardiogram were also monitored during all exercise tests.

Statistical analysis {#section19-1753466620939507}
--------------------

### Sample size calculation {#section20-1753466620939507}

We calculated that 40 completed patients would be necessary to identify a change of 0.75 in Borg dyspnea score between the two treatments, with an α of 0.05 and a β of 0.85. We purposely decided to power our study to detect a Borg dyspnea score difference lower than what is considered as the clinically meaningful difference for this variable (1 point)^[@bibr28-1753466620939507]^ in order to maximize statistical power. Expecting that 20% of patients would fail to reach a Borg dyspnea score of 3 or more at the 3-min CSST, we planned on recruiting up to 60 participants.

### Data analysis {#section21-1753466620939507}

Results are reported as mean ± SEM. For the primary outcome analysis of Borg dyspnea scores as well as for the secondary variables, comparisons of the values were made using an ANOVA model for a 2 × 2 cross-over design with repeated measurements within periods. The sources of variation included in the model were the sequence, period, treatment and time effect, as well as the following interaction terms: sequence \* period, period \* time, sequence \* time and treatment \* time. The normality assumption was verified by the Shapiro--Wilk statistic applied on the model residuals, and the homogeneity of variances by the traditional residual plots. All analyses were performed using SAS (SAS Institute Inc., NC, version 9.4) at the 0.05 significance level.

Results {#section22-1753466620939507}
=======

Between June 2016 and November 2018, we screened 95 patients, of which 50 entered the cross-over phase of the trial ([Figure 2](#fig2-1753466620939507){ref-type="fig"}). The majority of participants who were excluded (*n* = 34) did not meet the study inclusion criteria. From these 50 participants who contributed to the data analysis, 41 completed both treatment phases and nine completed only one treatment phase. Participants characteristics are outlined in [Table 1](#table1-1753466620939507){ref-type="table"}. The majority were on triple therapy with inhaled corticosteroids prior to study inclusion. On average, participants had moderate airflow limitation and exhibited an emphysematous physiological profile with an abnormally high FRC and abnormally low D~L~CO. Baseline ISWT performance and 3-min CSST speed determination are detailed in [Table 2](#table2-1753466620939507){ref-type="table"}. Most participants performed the 3-min CSST at 4.0 (34% of participants) or 5.0 km/h (44% of participants).

![Flow chart.\
COPD, chronic obstructive pulmonary disease; ICF, informed consent form; SAE, severe adverse event.](10.1177_1753466620939507-fig2){#fig2-1753466620939507}

###### 

Baseline demographics and participants characteristics (*n* = 50).

![](10.1177_1753466620939507-table1)

  Male, *n* (%)                                30 (60%)
  -------------------------------------------- -------------
  Age (years)                                  68 (7)
  **Race**                                     
  Caucasian, *n* (%)                           49 (98%)
  Other, *n* (%)                               1 (2%)
  **Smoking status**                           
  Ex-smokers, *n* (%)                          44 (88%)
  Current smokers, *n* (%)                     6 (12%)
  Smoking history (pack-years)                 57 (30)
  **MRC dyspnea scale, *n* (%)**               
  1                                            6 (12%)
  2                                            27 (54%)
  3                                            13 (26%)
  4                                            3 (6%)
  5                                            1 (2%)
  **Baseline pulmonary medication, *n* (%)**   
  Long-acting LAMA or LABA                     3 (6%)
  Long-acting LAMA and LABA                    12 (24%)
  LABA/ICS                                     5 (10%)
  LABA/LAMA and ICS                            30 (60%)
  Leukotriene antagonist                       2 (4%)
  PDE4 inhibitor                               4 (8%)
  **Other medication, *n* (%)**                
  ACE/ARB                                      14 (28%)
  β-blockers                                   6 (12%)
  Statins                                      16 (32%)
  Other hypolipidemic drugs                    1 (2%)
  Oral hypoglycemic agents                     8 (16%)
  **Pulmonary function at screening**          
  FEV~1~ post-bronchodilation (L)              1.38 (0.40)
  FEV~1~ post-bronchodilation (% predicted)    54 (11)
  FEV~1~/FVC (%)                               43.7 (7.4)
  FRC post-bronchodilation (L)                 4.42 (1.00)
  FRC post-bronchodilation (% predicted)       139 (24)
  D~L~CO (% predicted)                         57.6 (16.6)

Data are mean (SEM) unless indicated otherwise.

ACE, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; D~L~CO, carbon monoxide diffusion capacity; FEV~1~, forced expiratory volume in 1 s; FRC, functional residual volume; FVC, forced vital capacity; ICS, inhaled corticosteroids; LABA, long-acting β2-agonists; LAMA, long-acting muscarinic antagonists; MRC, medical research council; PDE4, phosphodiesterase-4 inhibitor.

###### 

Baseline incremental shuttle walk test (ISWT) performance and walking speed selection for the 3-min constant speed shuttle test (3-min CSST).

![](10.1177_1753466620939507-table2)

  ISWT                                        
  ------------------------------------------- -------------
  Endurance time (min)                        6.51 (0.19)
  Walking distance (m)                        380 (17)
  Borg dyspnea score at the end of test       5.7 (0.3)
  Borg leg fatigue score at the end of test   3.8 (0.4)
  IC at rest (L)                              2.44 (0.09)
  IC at end-exercise (L)                      1.79 (0.07)
  SpO~2~ at end-exercise test (%)             90.3 (0.5)
  3-min CSST speed, *n* (%)                   
  2.5 km/h                                    2 (4%)
  3.25 km/h                                   4 (8%)
  4.0 km/h                                    17 (34%)
  5.0 km/h                                    22 (44%)
  6.0 km/h                                    5 (10%)

Values are mean (SEM) unless indicated otherwise.

IC, inspiratory capacity; SpO~2~, pulsed arterial O~2~ saturation.

At baseline, mean Borg dyspnea score at the end of the 3-min CSST was 5.15 (0.25). After 3 weeks of treatment ([Figure 3(a)](#fig3-1753466620939507){ref-type="fig"}; [Table 3](#table3-1753466620939507){ref-type="table"}), both treatments provided statistically significant relief of exertional dyspnea. There was a 0.66 \[95% confidence interval (CI) −1.21 to −0.10)\]reduction in Borg dyspnea score from baseline with indacaterol/glycopyrronium while the corresponding value for tiotropium was 0.80 (95% CI −1.34 to −0.26), with a non-significant between-treatment difference of −0.15 (95% CI −0.40 to 0.70). After the first dose of study medication ([Figure 3(b)](#fig3-1753466620939507){ref-type="fig"}; [Table 3](#table3-1753466620939507){ref-type="table"}), the decrease in dyspnea was significant only for indacaterol/glycopyrronium (mean −1.00, 95% CI −1.49 to −0.50) but not with tiotropium (mean −0.36, 95% CI −0.81 to 0.09), with a significant between-treatment difference of −0.63 (95% CI −1.09 to −0.17).

![Borg dyspnea scores at the end of the 3-min constant speed shuttle test after 3 weeks of treatment (a), and after the first dose of study medication (b).\
Data are mean ± SEM. Numbers over the brackets indicate mean between-treatment differences. \*Indicates statistical significance (*p* \< 0.05).\
Ind/Gly, indacaterol/glycopyrronium; Tio, tiotropium.](10.1177_1753466620939507-fig3){#fig3-1753466620939507}

###### 

Borg dyspnea score at the end of the 3-min constant speed shuttle test (CSST) after 3 weeks of treatment and after the first dose.

![](10.1177_1753466620939507-table3)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
               Baseline      Ind/Gly       Change from baseline                                                  Tio           Change from baseline                                                  Ind/Gly *versus* Tio
  ------------ ------------- ------------- --------------------------------------------------------------------- ------------- --------------------------------------------------------------------- ---------------------------------------------------------------------
  First dose   5.15 (0.25)   4.16 (0.25)   −1.00 (0.25)[\*](#table-fn6-1753466620939507){ref-type="table-fn"}\   4.79 (0.23)   −0.36 (0.23)\                                                         −0.64 (0.23)[\*](#table-fn6-1753466620939507){ref-type="table-fn"}\
                                           \[−1.49 to −0.50\]                                                                  \[−0.81 to 0.09\]                                                     \[−1.09 to −0.17\]

  3-weeks      5.15 (0.25)   4.50 (0.28)   −0.66 (0.28)[\*](#table-fn6-1753466620939507){ref-type="table-fn"}\   4.35 (0.27)   −0.80 (0.27)[\*](#table-fn6-1753466620939507){ref-type="table-fn"}\   0.15 (0.28)\
                                           \[−1.21 to −0.10\]                                                                  \[−1.34 to −0.26\]                                                    \[−0.40 to 0.70\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are mean (SE) and 95% confidence intervals (in square brackets).

Indicates statistical significance (*p* \< 0.05).

Ind/Gly, indacaterol/glycopyrronium; Tio, tiotropium.

The impact of both treatment regimens on pulmonary function is provided in [Table 4](#table4-1753466620939507){ref-type="table"} and [Figure 4](#fig4-1753466620939507){ref-type="fig"}. Both treatments significantly improved expiratory flows and this was accompanied by evidence of lung deflation, notably increased inspiratory capacity (IC) and reduced FRC. Compared with tiotropium, indacaterol/glycopyrronium proved superior, as indicated by a 90 ml difference in FEV~1~ and a 140--170 ml difference in slow vital capacity (SVC) (both *p* \< 0.05). These differences were evident after the first dose of study medication and were sustained throughout the 3-week study duration. The further gain in FVC with indacaterol/glycopyrronium *versus* tiotropium alone was smaller and less consistent than with SVC. Compared with tiotropium alone, indacaterol/glycopyrronium led to additional improvement in IC (80--110 ml), and reduction in FRC (90--160 ml) and residual volume (RV) (130--220 ml), although these differences did not reach statistical significance at all time points.

###### 

Pulmonary function tests before and after first dose and 3 weeks of treatment.

![](10.1177_1753466620939507-table4)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                   Ind/Gly       Change from baseline                                                   Tio           Change from baseline                                                  Change Ind/Gly *versus* Tio
  ---------------- --------------- ------------- ---------------------------------------------------------------------- ------------- --------------------------------------------------------------------- ---------------------------------------------------------------------
  **FVC (L)**      Baseline        2.83 (0.14)                                                                                                                                                              

                   First dose\     3.26 (0.13)   0.44 (0.05)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\     3.14 (0.13)   0.32 (0.04)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\    0.11 (0.05)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\
                   (1 h 20 post)                 \[0.35 to 0.53\]                                                                     \[0.24 to 0.41\]                                                      \[0.02 to 0.21\]

                   3 weeks\        3.21 (0.13)   0.39 (0.06)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\     3.18 (0.13)   0.36 (0.07)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\    0.03 (0.08)\
                   (1 h 20 post)                 \[0.26 to 0.52\]                                                                     \[0.22 to 0.50\]                                                      \[−0.13 to 0.19\]

  **FEV~1~ (L)**   Baseline        1.15 (0.05)                                                                          1.15 (0.05)                                                                         

                   First dose\     1.36 (0.05)   0.21 (0.02)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\     1.27 (0.05)   0.12 (0.02)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\    0.09 (0.02)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\
                   (1 h 20 post)                 \[0.17 to 0.24\]                                                                     \[0.08 to 0.15\]                                                      \[0.05 to 0.13\]

                   3 weeks\        1.37 (0.05)   0.22 (0.03)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\     1.28 (0.05)   0.13 (0.03)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\    0.09 (0.02)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\
                   (1 h 20 post)                 \[0.18 to 0.28\]                                                                     \[0.08 to 0.18\]                                                      \[0.04 to 0.14\]

  **SVC (L)**      Baseline        3.07 (0.14)                                                                          3.07 (0.14)                                                                         

                   First dose\     3.49 (0.14)   0.42 (0.04)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\     3.32 (0.14)   0.25 (0.04)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\    0.17 (0.04)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\
                   (1 h 20 post)                 \[0.33 to 0.51\]                                                                     \[0.17 to 0.33\]                                                      \[0.08 to 0.25\]

                   3 weeks\        3.51 (0.14)   0.43 (0.05)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\     3.36 (0.14)   0.29 (0.05)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\    0.14 (0.05)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\
                   (1 h 20 post)                 \[0.33 to 0.54\]                                                                     \[0.20 to 0.38\]                                                      \[0.05 to 0.23\]

  **IC (L)**       Baseline        1.76 (0.08)                                                                          1.76 (0.08)                                                                         

                   First dose\     2.02 (0.08)   0.26 (0.04)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\     1.91 (0.08)   0.15 (0.04)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\    0.11 (0.04)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\
                   (1 h 20 post)                 \[0.18 to 0.33\]                                                                     \[0.08 to 0.22\]                                                      \[0.03 to 0.19\]

                   3 weeks\        2.05 (0.08)   0.291 (0.041)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\   1.97 (0.08)   0.21 (0.04)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\    0.082 (0.043)\
                   (1 h 20 post)                 \[0.21 to 0.37\]                                                                     \[0.13 to 0.29\]                                                      \[−0.003 to 0.17\]

  **FRC (L)**      Baseline        4.69 (0.15)                                                                          4.69 (0.15)                                                                         

                   First dose\     4.30 (0.15)   −0.40 (0.07)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\    4.39 (0.15)   −0.30 (0.06)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\   −0.09 (0.06)\
                   (1 h 20 post)                 \[−0.53 −0.25\]                                                                      \[−0.43 −0.18\]                                                       \[−0.21 0.04\]

                   3 weeks\        4.23 (0.16)   −0.46 (0.08)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\    4.39 (0.16)   −0.30 (0.08)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\   −0.16 (0.08)\
                   (1 h 20 post)                 \[−0.62 to −0.31\]                                                                   \[−0.46 to −0.14\]                                                    \[−0.32 to 0.002\]

  **RV (L)**       Baseline        3.39 (0.13)                                                                          3.39 (0.13)                                                                         

                   First dose\     2.84 (0.14)   −0.54 (0.08)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\    2.98 (0.14)   −0.41 (0.08)\                                                         −0.13 (0.08)\
                   (1 h 20 post)                 \[−0.71 to −0.38\]                                                                   \[−0.56 to −0.26\]                                                    −0.29 to 0.02

                   3 weeks\        2.77 (0.16)   −0.62 (0.10)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\    3.00 (0.16)   −0.40 (0.10)\                                                         −0.22 (0.10)[\*](#table-fn9-1753466620939507){ref-type="table-fn"}\
                   (1 h 20 post)                 \[−0.81 to −0.42\]                                                                   \[−0.59 to −0.20\]                                                    \[−0.42 to −0.02\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are mean (SEM) and 95% confidence intervals (in square brackets). Baseline values for the pulmonary function variables are the average of those obtained before the administration of study medication at visits 4 and 6.

Indicates statistical significance (*p* \< 0.05).

FEV~1~, forced expiratory volume in 1 s; FRC, functional residual capacity; FVC, forced vital capacity; IC, inspiratory capacity; Ind/Gly, indacaterol/glycopyrronium; RV, residual volume; SVC, slow vital capacity; Tio, tiotropium.

![Changes from baseline in slow vital capacity (SVC), forced vital capacity (FVC), forced expiratory volume in 1 s (FEV~1~), inspiratory capacity (IC), functional residual capacity (FRC) and residual volume (RV) after the first dose ((a) and (c)) or after 3 weeks of therapy ((b) and (d)) of either indacaterol/glycopyrronium or tiotropium alone. Results are expressed in L ((a) and (b)) and in percentage change from baseline ((c) and (d)).\
\*Indicates statistical significance (*p* \< 0.05).](10.1177_1753466620939507-fig4){#fig4-1753466620939507}

The effects of indacaterol/glycopyrronium and tiotropium on TDI and CAT scores are shown in [Table 5](#table5-1753466620939507){ref-type="table"}. As can be seen, at week 3 there was a 0.99-point improvement in TDI with indacaterol/glycopyrronium leading to a 1.27-point between-treatment difference. Although this value is considered to be above the clinically meaningful threshold for this variable,^[@bibr29-1753466620939507]^ this difference did not reach statistical significance. Changes in CAT scores with both therapies were small and statistically non-significant.

###### 

Transitional dyspnea index (TDI) total scores and COPD Assessment Test scores (CAT) after 3 weeks of treatment.

![](10.1177_1753466620939507-table5)

  -----------------------------------------------------------------------------------------------------------------------
        Baseline       Ind/Gly        Change from baseline   Tio            Change from baseline   Ind/Gly *versus* Tio
  ----- -------------- -------------- ---------------------- -------------- ---------------------- ----------------------
  TDI   --             0.99 (0.54)    --                     −0.28 (0.53)                          1.27 (0.76)\
                                                                                                   \[−0.26 to 2.80\]

  CAT   14.61 (1.17)   13.15 (1.23)   −1.46 (0.84)\          14.10 (1.21)   −0.51 (0.78)\          −0.95 (0.76)\
                                      \[−3.12 to 0.21\]                     \[−2.06 to 1.04\]      \[−2.47 to 0.57\]
  -----------------------------------------------------------------------------------------------------------------------

Values are mean (SEM) and 95% confidence intervals (in square brackets). Baseline values for the CAT are the average of those obtained before the administration of study medication at visits 4 and 6.

Indicates statistical significance (*p* \< 0.05).

CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; Ind/Gly, indacaterol/glycopyrronium; TDI, transition dyspnea index; Tio, tiotropium.

Cardiopulmonary responses to exercise are depicted in [Figure 5](#fig5-1753466620939507){ref-type="fig"}. Compared with baseline, indacaterol/glycopyrronium led to small reductions in B~f~ with increases in VT, whose statistical significance was variable over time during the 3-min CSST and visits. There were no statistically significant differences for these variables between the two treatments.

![Breathing frequency (B~f~), tidal volume (VT) and minute ventilation (VE) during the 3-min constant speed shuttle test after the first dose of study medication ((a), (c), and (e)) and after 3 weeks of treatment ((b), (d) and (f)).\
Data are mean ± SEM. \*Indicates statistical significance (*p* \< 0.05).](10.1177_1753466620939507-fig5){#fig5-1753466620939507}

No safety concerns were seen with either medication. Seven patients experienced a COPD exacerbation during the trial (indacaterol/glycopyrronium, *n* = 2; tiotropium, *n* = 2, washout period, *n* = 3) ([Table 6](#table6-1753466620939507){ref-type="table"}). No adverse events were felt to be related to the study medication or the study procedures. The exercise tests were well tolerated in all study participants, with no adverse events related to these procedures.

###### 

Adverse events.

![](10.1177_1753466620939507-table6)

                                    Indacaterol/glycopyrronium   Tiotropium   Washout
  --------------------------------- ---------------------------- ------------ ---------
  **AE, *n***                                                                 
   AE                               4                            2            11
   Drug-related AE                  0                            0            0
   AE leading to study withdrawal   1                            2            4
  **SAE, *n***                                                                
   Non-fatal SAE                    2                            0            2
   Drug-related non-fatal SAE       0                            0            0
   Fatal SAE                        0                            1            0
   Drug-related fatal SAE           0                            0            0
  **Most frequent AEs, *n***                                                  
   COPD exacerbation                2                            2            3
   Pneumonia                        0                            0            1
   Progression of neoplasia         0                            1            1
   Pneumothorax                     0                            0            1
   Pancreatitis                     1                            0            0
   Cough and headache               2                            0            2
   Loss of consciousness            1                            0            0
   Chest pain                       0                            0            3
   Bronchospasm                     0                            0            1
   Hip pain                         0                            0            1

AE, adverse event; COPD, chronic obstructive pulmonary disease; SAE, serious adverse event.

Discussion {#section23-1753466620939507}
==========

In the present study, indacaterol/glycopyrronium provided greater bronchodilation and lung deflation compared with tiotropium alone, and this translated into further exertional dyspnea relief after the first dosage of medication. Despite maintaining its efficacy to improve expiratory flows and lung volumes throughout the study, the added benefits of indacaterol/glycopyrronium on exertional dyspnea were not apparent after 3 weeks of treatment.

Two active bronchodilator treatments were assessed and compared in this trial. As expected from their known efficacy profile, both indacaterol/glycopyrronium and tiotropium provided potent bronchodilation and lung deflation on order of magnitude consistent with previous reports.^[@bibr8-1753466620939507],[@bibr20-1753466620939507],[@bibr30-1753466620939507]^ These beneficial effects on lung function were accompanied by a significant reduction in dyspnea intensity ratings at the end of the 3-min CSST immediately after the first dose of indacaterol/glycopyrronium, and after 3 weeks. Tiotropium alone reduced exertional dyspnea perception after 3 weeks of treatment but not after the first dose, a finding that is consistent with the previously reported progressive efficacy build-up over a 3--6-week course of treatment.^[@bibr7-1753466620939507]^ As a result of these differential responses to indacaterol/glycopyrronium and tiotropium, there was a clinically meaningful one-point reduction in Borg dyspnea score^[@bibr28-1753466620939507]^ at the end of the 3-min CSST in favor of indacaterol/glycopyrronium after the first dose but this difference was not sustained after 3 weeks of therapy.

In line with previous trials,^[@bibr20-1753466620939507],[@bibr30-1753466620939507]^ we found that indacaterol/glycopyrronium provided superior bronchodilation, as evidenced by a 90 ml difference in trough FEV~1~ *versus* tiotropium, an effect that was already present after the first dose and sustained at 3 weeks. Moreover, the 140--170 ml difference in trough SVC indicated further volume recruitment with dual bronchodilation, a reflection of reduced gas trapping, an important contributor to exercise intolerance and dyspnea generation in COPD.^[@bibr31-1753466620939507][@bibr32-1753466620939507]--[@bibr33-1753466620939507]^ Interestingly, we found that the SVC results allowed better differentiation between dual and mono bronchodilator therapy than FVC, a likely reflection of dynamic airway compression, small airway closure and gas trapping during forced expiratory maneuvers.^[@bibr34-1753466620939507],[@bibr35-1753466620939507]^ As such, SVC may better reflect lung volume recruitment with bronchodilation than FVC measurements.^[@bibr33-1753466620939507]^ Consistent with this, we confirmed the added benefit of indacaterol/glycopyrronium over tiotropium to increase resting IC by 80--110 ml, the magnitude of which was similar to a previous report.^[@bibr30-1753466620939507]^ There was an impressive 400--460 ml reduction in FRC with indacaterol/glycopyrronium compared with baseline, but the between-treatment difference did not reach statistical significance, likely reflecting higher variability of lung volume measurements in clinical trials like ours.^[@bibr30-1753466620939507]^ Overall, the magnitude of bronchodilation and lung deflation reported herein was as expected from the known efficacy profile of the two bronchodilator regimens. However, the between-treatment differences in expiratory flows and lung deflation were likely smaller than what is necessary to differentiate the two treatments on the basis of exertional dyspnea relief. For example, differences in IC in the range of 100--250 ml are likely necessary for lung deflation to translate into reduced exertional dyspnea.^[@bibr7-1753466620939507],[@bibr8-1753466620939507]^

Our findings are somewhat at variance with the OTIVATO trial, in which dual bronchodilation with tiotropium/olodaterol was associated with a statistically significant 0.36-point reduction in Borg dyspnea score compared with tiotropium after 6 weeks of therapy,^[@bibr19-1753466620939507]^ as opposed to a non-significant between-treatment difference in the present study. There are several potential explanations for this apparent discrepancy between the two trials. First, the time frame was different; in OTIVATO, each treatment phase lasted 6 weeks as compared with 3 weeks in the present trial. In this regard, it is interesting to note that in the OTIVATO trial, the further reduction in exertional dyspnea between dual *versus* monobronchodilator therapy did not emerge at 3 weeks.^[@bibr19-1753466620939507]^ In the present trial, we elected for 3-week treatment periods for several reasons. First, this duration of treatment was felt to be sufficient to allow bronchodilation to impact on dyspnea.^[@bibr7-1753466620939507]^ Second, shorter treatment periods also imply shorter overall study duration, which may help minimize participant attrition during the study. Participants demographics at baseline were similar between the OTIVATO trial and the present study except for resting FRC, which was lower in the present trial (139% *versus* 155% predicted in the OTIVATO trial). This might have impacted on the ability of bronchodilation to reduce exertional dyspnea, considering that the degree of resting hyperinflation is an important determinant of the dyspnea response to bronchodilation in patients with COPD.^[@bibr36-1753466620939507]^ A key difference between OTIVATO and the present trial was the IC response to bronchodilation; in OTIVATO, there was a 218 ml improvement with dual bronchodilation compared with tiotropium alone, while in the present trial the improvement was 80--110 ml. Considering the important implication for the improvement in IC to dyspnea relief during exertion,^[@bibr7-1753466620939507]^ this important difference between the studies is likely to be a key in understanding the apparent discrepancy of the results.

Whether or not dual bronchodilation further improves dyspnea and exercise capacity outcomes over what can be achieved with one long-acting bronchodilator alone has been a long-standing debate because clear treatment differences do not always emerge in individual trials.^[@bibr30-1753466620939507],[@bibr37-1753466620939507],[@bibr38-1753466620939507]^ We consider that the present results are in line with the clinical research experience in comparing dual *versus* monobronchodilation in COPD. However, when results from individual studies are combined in a systematic fashion, the conclusion is that dual bronchodilation provides the best chance for an optimal dyspnea and exercise capacity status in patients with COPD.^[@bibr39-1753466620939507],[@bibr40-1753466620939507]^ Using a non-randomized study design, Benavides-Cordoba and colleagues provided supporting evidence for an exercise-enhancing effect of dual bronchodilation *versus* monobronchodilation in the context of pulmonary rehabilitation.^[@bibr41-1753466620939507]^ This interesting concept should be further explored in a more stringent randomized controlled study design.

The 3-min CSST was designed to allow a specific evaluation of the impact of therapies such as bronchodilators on exertional dyspnea.^[@bibr16-1753466620939507]^ Because of its fixed duration, the 3-min CSST does not allow us to quantify the impact of therapies on exercise capacity. Together with the OTIVATO trial, we showed that the 3-min CSST can be used in the context of multicenter trials. With this testing modality, in both trials we succeeded in generating clinically important ratings of exertional dyspnea that were amenable to therapy (Borg ⩾ 4). There are, however, some limitations to our trial. The relatively small number of patients, even with a cross-over design, could have underpowered this trial and makes the generalizability of the data uncertain. Despite the fact that this was taken into consideration in the statistical plan, a carry-over effect with this type of design cannot be entirely excluded. Moreover, although we elected for a relatively short 3-week treatment period in order to minimize participant attrition, this decision might have influenced the possibility for the dual bronchodilation to fully express its potential to further alleviate exertional dyspnea compared with monobronchodilation.

Activity-related dyspnea can be assessed with specific task-based dyspnea questionnaires such as the TDI. One important difference between using a task-based questionnaire *versus* using the 3-min CSST to assess for changes in exertional dyspnea is the absence of a standardized exercise stimulus with the former approach. With the 3-min CSST, the shuttle speed is constant and externally imposed, ensuring precise control of the exercise stimulus. Nevertheless, previous investigators have succeeded at demonstrating reduction in dyspnea with bronchodilation using the TDI questionnaire. For example, two trials comparing dual *versus* monobronchodilation reported a 0.5-point difference in TDI score, a difference that was smaller compared with that seen when active monobronchodilation is compared with placebo.^[@bibr21-1753466620939507],[@bibr42-1753466620939507]^ In the present trial, we were not successful at showing a statistically significant dyspnea benefit of indacaterol/ glycopyrronium over tiotropium alone with the TDI, although the 1.27-point treatment difference was numerically larger than the minimally important difference for this variable and the treatment difference reported in previous trials.^[@bibr21-1753466620939507],[@bibr42-1753466620939507]^ A type II error could have contributed to this lack of statistical difference.

Conclusion {#section24-1753466620939507}
==========

In comparison with bronchodilator monotherapy, dual bronchodilation provided greater immediate exertional dyspnea relief but this difference was not sustained after 3 weeks of therapy despite sustained expiratory flow and lung deflation benefits throughout the trial.
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